Company Description
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 628 |
| CEO | Richard Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
| Phone | 844 696 5235 |
| Website | immunitybio.com |
Stock Details
| Ticker Symbol | IBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326110 |
| CUSIP Number | 45256X103 |
| ISIN Number | US45256X1037 |
| Employer ID | 43-1979754 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Richard Gerald Adcock | President, Chief Executive Officer and Director |
| Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board and Global Chief Scientific and Medical Officer |
| David C. Sachs | Chief Financial Officer |
| Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
| Dr. Leonard S. Sender M.D. | Chief Operating Officer |
| Regan J. Lauer | Chief Accounting Officer |
| Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
| Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
| Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
| Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Jul 18, 2024 | 8-K | Current Report |
| Jun 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 12, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | EFFECT | Notice of Effectiveness |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |